OncoMatch/Clinical Trials/NCT06909877
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Is NCT06909877 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies HH2853 Tablets for relapsed/refractory peripheral t-cell lymphoma (r/r ptcl).
Treatment: HH2853 Tablets — This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systematic combination chemotherapy
Patients must have histologically confirmed diagnosis of R/R PTCL who have received at least one line of prior systematic combination chemotherapy and at least one new drug therapy (prior antitumor treatment lines ≤4 lines) : relapse and/or refractory.
Must have received: new drug therapy
at least one new drug therapy (prior antitumor treatment lines ≤4 lines) : relapse and/or refractory.
Cannot have received: EZH2 inhibitor
Previous treatment with EZH2 or EZH1/2 inhibitors
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06909877 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EZH2 inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages